Obagi Medical Products, Inc. OMPI announced the publication of a study showing that the use of its Condition & Enhance System (also marketed as Nu-Derm), when combined with Botulinum Toxin Type A treatments (BOTOX®), provides greater improvement in overall facial appearance, as well as increased patient satisfaction, vs. BOTOX treatments with
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in